Relmada Therapeutics Inc (RLMD)
3.925
+0.06
(+1.42%)
USD |
NASDAQ |
Apr 23, 12:16
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 118.43M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 46.59% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.388 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 95.67% |
Profile
| Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
| URL | https://www.relmada.com |
| Investor Relations URL | https://www.relmada.com/investors |
| HQ State/Province | Florida |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 19, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
| URL | https://www.relmada.com |
| Investor Relations URL | https://www.relmada.com/investors |
| HQ State/Province | Florida |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 19, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |